This Drug Discovery Outsourcing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The drug discovery outsourcing market size has grown strongly in recent years. It will grow from $3.92 billion in 2024 to $4.24 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the growing complexity of drug discovery, the need for specialized expertise, stringent regulatory requirements, the globalization of clinical trials, and the rise in demand for orphan drugs and personalized medicine.
The drug discovery outsourcing market size is expected to see strong growth in the next few years. It will grow to $5.72 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing expenses in research and development, patent expirations, the expansion of the biopharmaceutical sector, focus on core competencies, and pressure to reduce time-to-market. Major trends in the forecast period include the adoption of artificial intelligence, technological advancements, big data analytics, specialty drugs, and collaboration and strategic partnerships.
The increasing prevalence of chronic diseases is likely to drive the growth of the drug discovery outsourcing market. Chronic diseases, which are long-term health conditions that can persist for years or a lifetime, are becoming more common due to factors such as an aging population, lifestyle choices, urbanization, and environmental influences. Outsourcing drug discovery helps expedite the development of treatments for chronic diseases by providing access to specialized expertise and advanced technologies, thereby reducing time and costs. For example, in June 2024, the Australian Institute of Health and Welfare reported that 61% of the Australian population, about 15.4 million people, had at least one long-term health condition, which contributed to 90% of deaths in 2022. Conditions like anxiety affected 1.3 million (16%) of individuals aged 0-24 and 1.6 million (22%) of those aged 25-44. Back problems were noted in 1.5 million (23%) of people aged 45-64, and 1.3 million (32%) of individuals aged 65 and older experienced deafness or hearing loss. This rising prevalence of chronic diseases is fueling growth in the drug discovery outsourcing market.
Companies in the drug discovery outsourcing sector are focusing on innovations such as digital health solutions to better serve healthcare professionals, regulators, and patients. Digital health solutions include technologies and services like telemedicine, mobile health apps, and wearable devices that improve healthcare delivery, patient engagement, and health management. For instance, in November 2023, AstraZeneca PLC, a UK-based biopharmaceutical company, introduced Evinova, a health-tech business aimed at advancing life sciences innovation and improving clinical trial delivery. Evinova focuses on global digital products and services that have demonstrated effectiveness in AstraZeneca's clinical trials across more than 40 countries. By enhancing clinical trial design and execution, Evinova aims to streamline new medicine development, reducing both time and costs.
In July 2024, Selvita SA, a Poland-based company specializing in drug discovery, research, and development services, acquired PozLab for an undisclosed sum. This acquisition strengthens Selvita’s capabilities in drug development, positioning the company as a comprehensive solution provider in the pharmaceutical industry and expanding its offerings to include small molecule drug manufacturing services for early-stage clinical trials. PozLab is a Poland-based contract development organization that provides end-to-end pharmaceutical development services.
Major companies operating in the drug discovery outsourcing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Eurofins SE, Charles River Laboratories, QIAGEN N.V., Curia Global Inc., EVOTEC, Pharmaron Beijing Co. Ltd., Genscript Biotech, WuXi AppTec, Pharmaceutical Product Development, LLC, Syngene International Limited, Jubilant Biosys, Dalton Pharma Services, Oncodesign Services, DiscoverX Corp., Domainex Ltd., Exscientia, TCG Lifesciences Pvt Ltd., GVK Biosciences Private Limited.
North America was the largest region in the drug discovery outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug discovery outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Drug discovery outsourcing involves pharmaceutical companies contracting external organizations to handle various stages of the drug discovery process, such as target identification, lead optimization, and preclinical testing. This practice leverages specialized expertise, reduces costs, and speeds up development timelines.
The main types of drug discovery outsourcing include chemistry services and biological services. Chemistry services encompass specialized chemical expertise, including the synthesis, analysis, and optimization of drug candidates. The workflow typically involves target identification and screening, target validation and functional informatics, lead identification and candidate optimization, and preclinical development. Disease models used in these services include in vitro models, animal models, and cellular models. These services cater to various therapeutic areas, such as cardiovascular, central nervous system (CNS), gastrointestinal, hematology, respiratory, infectious diseases, oncology, immunology, and more. End users include pharmaceutical and biotechnology companies, academic institutions, and other organizations.
The drug discovery outsourcing market research report is one of a series of new reports that provides drug discovery outsourcing market statistics, including the drug discovery outsourcing industry's global market size, regional shares, competitors with a drug discovery outsourcing market share, detailed drug discovery outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery outsourcing industry. This drug discovery outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The drug discovery outsourcing market includes revenues earned by entities by providing services such as trial design, site management, patient recruitment, and data collection and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The drug discovery outsourcing market size has grown strongly in recent years. It will grow from $3.92 billion in 2024 to $4.24 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the growing complexity of drug discovery, the need for specialized expertise, stringent regulatory requirements, the globalization of clinical trials, and the rise in demand for orphan drugs and personalized medicine.
The drug discovery outsourcing market size is expected to see strong growth in the next few years. It will grow to $5.72 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing expenses in research and development, patent expirations, the expansion of the biopharmaceutical sector, focus on core competencies, and pressure to reduce time-to-market. Major trends in the forecast period include the adoption of artificial intelligence, technological advancements, big data analytics, specialty drugs, and collaboration and strategic partnerships.
The increasing prevalence of chronic diseases is likely to drive the growth of the drug discovery outsourcing market. Chronic diseases, which are long-term health conditions that can persist for years or a lifetime, are becoming more common due to factors such as an aging population, lifestyle choices, urbanization, and environmental influences. Outsourcing drug discovery helps expedite the development of treatments for chronic diseases by providing access to specialized expertise and advanced technologies, thereby reducing time and costs. For example, in June 2024, the Australian Institute of Health and Welfare reported that 61% of the Australian population, about 15.4 million people, had at least one long-term health condition, which contributed to 90% of deaths in 2022. Conditions like anxiety affected 1.3 million (16%) of individuals aged 0-24 and 1.6 million (22%) of those aged 25-44. Back problems were noted in 1.5 million (23%) of people aged 45-64, and 1.3 million (32%) of individuals aged 65 and older experienced deafness or hearing loss. This rising prevalence of chronic diseases is fueling growth in the drug discovery outsourcing market.
Companies in the drug discovery outsourcing sector are focusing on innovations such as digital health solutions to better serve healthcare professionals, regulators, and patients. Digital health solutions include technologies and services like telemedicine, mobile health apps, and wearable devices that improve healthcare delivery, patient engagement, and health management. For instance, in November 2023, AstraZeneca PLC, a UK-based biopharmaceutical company, introduced Evinova, a health-tech business aimed at advancing life sciences innovation and improving clinical trial delivery. Evinova focuses on global digital products and services that have demonstrated effectiveness in AstraZeneca's clinical trials across more than 40 countries. By enhancing clinical trial design and execution, Evinova aims to streamline new medicine development, reducing both time and costs.
In July 2024, Selvita SA, a Poland-based company specializing in drug discovery, research, and development services, acquired PozLab for an undisclosed sum. This acquisition strengthens Selvita’s capabilities in drug development, positioning the company as a comprehensive solution provider in the pharmaceutical industry and expanding its offerings to include small molecule drug manufacturing services for early-stage clinical trials. PozLab is a Poland-based contract development organization that provides end-to-end pharmaceutical development services.
Major companies operating in the drug discovery outsourcing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Eurofins SE, Charles River Laboratories, QIAGEN N.V., Curia Global Inc., EVOTEC, Pharmaron Beijing Co. Ltd., Genscript Biotech, WuXi AppTec, Pharmaceutical Product Development, LLC, Syngene International Limited, Jubilant Biosys, Dalton Pharma Services, Oncodesign Services, DiscoverX Corp., Domainex Ltd., Exscientia, TCG Lifesciences Pvt Ltd., GVK Biosciences Private Limited.
North America was the largest region in the drug discovery outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug discovery outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Drug discovery outsourcing involves pharmaceutical companies contracting external organizations to handle various stages of the drug discovery process, such as target identification, lead optimization, and preclinical testing. This practice leverages specialized expertise, reduces costs, and speeds up development timelines.
The main types of drug discovery outsourcing include chemistry services and biological services. Chemistry services encompass specialized chemical expertise, including the synthesis, analysis, and optimization of drug candidates. The workflow typically involves target identification and screening, target validation and functional informatics, lead identification and candidate optimization, and preclinical development. Disease models used in these services include in vitro models, animal models, and cellular models. These services cater to various therapeutic areas, such as cardiovascular, central nervous system (CNS), gastrointestinal, hematology, respiratory, infectious diseases, oncology, immunology, and more. End users include pharmaceutical and biotechnology companies, academic institutions, and other organizations.
The drug discovery outsourcing market research report is one of a series of new reports that provides drug discovery outsourcing market statistics, including the drug discovery outsourcing industry's global market size, regional shares, competitors with a drug discovery outsourcing market share, detailed drug discovery outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery outsourcing industry. This drug discovery outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The drug discovery outsourcing market includes revenues earned by entities by providing services such as trial design, site management, patient recruitment, and data collection and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Drug Discovery Outsourcing Market Characteristics3. Drug Discovery Outsourcing Market Trends and Strategies4. Drug Discovery Outsourcing Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Drug Discovery Outsourcing Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Drug Discovery Outsourcing Market34. Recent Developments in the Drug Discovery Outsourcing Market
5. Global Drug Discovery Outsourcing Growth Analysis and Strategic Analysis Framework
6. Drug Discovery Outsourcing Market Segmentation
7. Drug Discovery Outsourcing Market Regional and Country Analysis
8. Asia-Pacific Drug Discovery Outsourcing Market
9. China Drug Discovery Outsourcing Market
10. India Drug Discovery Outsourcing Market
11. Japan Drug Discovery Outsourcing Market
12. Australia Drug Discovery Outsourcing Market
13. Indonesia Drug Discovery Outsourcing Market
14. South Korea Drug Discovery Outsourcing Market
15. Western Europe Drug Discovery Outsourcing Market
16. UK Drug Discovery Outsourcing Market
17. Germany Drug Discovery Outsourcing Market
18. France Drug Discovery Outsourcing Market
19. Italy Drug Discovery Outsourcing Market
20. Spain Drug Discovery Outsourcing Market
21. Eastern Europe Drug Discovery Outsourcing Market
22. Russia Drug Discovery Outsourcing Market
23. North America Drug Discovery Outsourcing Market
24. USA Drug Discovery Outsourcing Market
25. Canada Drug Discovery Outsourcing Market
26. South America Drug Discovery Outsourcing Market
27. Brazil Drug Discovery Outsourcing Market
28. Middle East Drug Discovery Outsourcing Market
29. Africa Drug Discovery Outsourcing Market
30. Drug Discovery Outsourcing Market Competitive Landscape and Company Profiles
31. Drug Discovery Outsourcing Market Other Major and Innovative Companies
35. Drug Discovery Outsourcing Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Drug Discovery Outsourcing Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on drug discovery outsourcing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug discovery outsourcing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drug discovery outsourcing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Service Type: Chemistry Services; Biological Services2) By Workflow: Target Identification and Screening; Target Validation and Functional Informatics; Lead Identification and Candidate Optimization; Preclinical Development; Other Workflows
3) By Disease Model: in Vitro Models; Animal Models; Cellular Models; Other Disease Models
4) By Therapeutic Area: Cardiovascular; Central Nervous System (CNS); Gastrointestinal; Hematology; Respiratory System; Infectious Disease; Oncology; Immunology; Other Therapeutic Areas
5) By End User: Pharmaceutical and Biotechnology Companies; Academic Institutes; Other End Users
Subsegments:
1) By Chemistry Services: Custom Synthesis and Manufacturing; Medicinal Chemistry; Combinatorial Chemistry; Hit Identification and Lead Optimization; Process Chemistry and Scale-Up; Analytical Chemistry Services; Chemical Library Design and Screening; ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Profiling2) By Biological Services: Cell-Based Assays and Screening; Target Identification and Validation; in Vitro and in Vivo Testing; Biomarker Discovery and Development; Toxicology Studies; Genomics and Proteomics Services; Animal Models for Preclinical Development; Biological Safety and Efficacy Testing; Biopharmaceutical Development and Manufacturing.
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Eurofins SE; Charles River Laboratories; QIAGEN N.V.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Drug Discovery Outsourcing market report include:- Thermo Fisher Scientific Inc.
- Laboratory Corporation of America Holdings
- Eurofins SE
- Charles River Laboratories
- QIAGEN N.V.
- Curia Global Inc.
- EVOTEC
- Pharmaron Beijing Co. Ltd.
- Genscript Biotech
- WuXi AppTec
- Pharmaceutical Product Development, LLC
- Syngene International Limited
- Jubilant Biosys
- Dalton Pharma Services
- Oncodesign Services
- DiscoverX Corp.
- Domainex Ltd.
- Exscientia
- TCG Lifesciences Pvt Ltd.
- GVK Biosciences Private Limited
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | April 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 4.24 Billion |
Forecasted Market Value ( USD | $ 5.72 Billion |
Compound Annual Growth Rate | 7.8% |
Regions Covered | Global |
No. of Companies Mentioned | 21 |